Details of the Drug

General Information of Drug (ID: DMTL94F)

Drug Name
Maraviroc
Synonyms
376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; MVC; CHEMBL1201187; CHEBI:63608; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; Maraviroc [USAN]; Celsentri (TN); Celsentri(TM); PRO 140 & Maraviroc; Selzentry (TN); Selzentry(TM); UK-427,857 maraviroc (MVC); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; [3H]maraviroc
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Chronic obstructive pulmonary disease CA22 Phase 3 [1]
Therapeutic Class
Anti-HIV Agents
Affected Organisms
Human Immunodeficiency Virus
ATC Code
J05AX09: Maraviroc
J05AX: Other antivirals
J05A: DIRECT ACTING ANTIVIRALS
J05: ANTIVIRALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 513.7
Logarithm of the Partition Coefficient (xlogp) 5.1
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability
The bioavailability of drug is 23% []
Clearance
The drug present in the plasma can be removed from the body at the rate of 9.4 mL/min/kg [3]
Elimination
8% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 14 - 18 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 33.373 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.25% [3]
Vd
The volume of distribution (Vd) of drug is 194 L []
Chemical Identifiers
Formula
C29H41F2N5O
IUPAC Name
4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
Canonical SMILES
CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
InChI
InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1
InChIKey
GSNHKUDZZFZSJB-HLMSNRGBSA-N
Cross-matching ID
PubChem CID
3002977
ChEBI ID
CHEBI:63608
CAS Number
376348-65-1
UNII
MD6P741W8A
DrugBank ID
DB04835
TTD ID
D0NR6S
VARIDT ID
DR00730
ACDINA ID
D00384
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 5 (CCR5) TT2CEJG CCR5_HUMAN Antagonist [5]
CCR5 messenger RNA (CCR5 mRNA) TTJIH8Q CCR5_HUMAN Antagonist [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 12 Disease of the respiratory system
Disease Class ICD-11: CA23 Asthma
The Studied Tissue Lung tissue
The Studied Disease Chronic obstructive pulmonary disease [ICD-11:CA23]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
C-C chemokine receptor type 5 (CCR5) DTT CCR5 5.10E-01 0.03 0.05
C-C chemokine receptor type 5 (CCR5) DTT CCR5 5.43E-01 1.04E-02 0.02
P-glycoprotein 1 (ABCB1) DTP P-GP 1.24E-01 -4.12E-01 -4.68E-01
P-glycoprotein 1 (ABCB1) DTP P-GP 3.00E-02 -1.09E-02 -7.37E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U2OS CTRP1 7.0676 9.5729 4.1746 2.5759
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MCF-7 CTRP1 6.4077 10.4266 3.3988 9.9439
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GaMG CTRP1 6.6198 8.2025 4.5195 1.1156
SF295 CTRP1 6.9588 8.3087 4.6192 0.3896
LN-229 CTRP1 7.0182 8.8068 4.4588 1.0031
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-265 CTRP1 4.7539 10.0066 2.3265 23.9035
KLE CTRP1 6.3573 9.0087 4.0325 5.0391
HEC-151 CTRP1 6.4187 8.9902 4.0775 4.5384
HEC-59 CTRP1 6.5402 9.8809 3.7421 6.8738
JHUEM-2 CTRP1 7.0232 8.9962 4.3875 1.3635
HEC-6 CTRP1 7.0804 13.085 2.5798 13.8196
MFE-319 CTRP1 7.3892 13.3988 2.6343 12.6121
HEC-108 CTRP1 7.5623 12.9131 2.9701 9.9433
HEC-251 CTRP1 8.7382 17.4309 1.6043 15.1173
Ishikawa (Heraklio) 02 ER- CTRP1 6.7444 10.6384 3.5175 8.0819
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NU-DUL-1 CTRP1 4.3559 7.1838 3.3658 18.3053
KE-97 CTRP1 4.6974 11.9924 1.2865 29.5039
P3HR-1 CTRP1 4.7644 8.6529 3.011 19.1478
BL-70 CTRP1 5.8062 8.7973 3.77 8.7986
SU-DHL-5 CTRP1 5.9551 8.2091 4.1534 5.1057
NOMO-1 CTRP1 6.3153 7.6902 4.5845 1.1264
MC116 CTRP1 6.4337 7.4909 4.7118 0.3837
Ku812 CTRP1 6.5456 8.8741 4.2014 3.3229
U-937 CTRP1 6.6325 8.6756 4.3325 2.2432
RPMI-8226 CTRP1 6.6353 8.1131 4.5612 0.8803
OCI-AML-3 CTRP1 6.6569 8.0562 4.5921 0.7113
SKM-1 CTRP1 6.6864 9.8102 3.8635 5.5655
KMS-11 CTRP1 6.7042 10.2835 3.6572 7.1122
LP-1 CTRP1 6.7631 9.0861 4.2256 2.7431
EJM CTRP1 6.8541 8.5004 4.5062 0.933
WSU-DLCL2 CTRP1 6.9264 8.0083 4.712 0.1568
AMO1 CTRP1 6.9478 8.1295 4.6781 0.2258
PL21 CTRP1 7.0989 8.5761 4.5769 0.4511
MOLM-16 CTRP1 7.1582 8.6921 4.5579 0.4812
SU-DHL-4 CTRP1 7.2531 8.508 4.6569 0.1732
THP-1 CTRP1 7.2534 9.1247 4.4368 0.8912
HT CTRP1 7.3448 13.6515 2.4857 13.6791
GDM-1 CTRP1 7.4378 9.5882 4.3384 1.178
OCI-Ly10 CTRP1 8.0098 16.2209 1.7041 16.3841
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
VMRC-RCW CTRP1 6.8587 11.5063 3.1834 10.2769
RCC10RGB CTRP1 7.2983 8.6394 4.6281 0.2196
Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
C2BBe1 CTRP1 4.9888 11.3394 1.86 25.5289
CW-2 CTRP1 5.0173 6.735 4.186 8.0399
COLO 320 CTRP1 5.2088 7.6352 3.8935 9.8756
SW48 CTRP1 5.268 11.5446 1.9886 23.6722
DLD-1 CTRP1 5.6392 8.0227 4.0283 7.1296
LS123 CTRP1 5.7079 7.5478 4.3048 4.5318
GP2d CTRP1 5.9932 13.5439 1.5676 23.1551
LS411N CTRP1 6.1379 8.7332 4.0243 5.6721
LS513 CTRP1 6.1794 8.8762 3.9837 5.8924
COLO205 CTRP1 6.2039 8.0037 4.3956 2.5838
SK-CO-1 CTRP1 6.3344 9.5384 3.772 7.1886
SNU-175 CTRP1 6.3694 8.6284 4.2117 3.6158
HCT 116 CTRP1 6.3744 8.4216 4.306 2.9006
HT-29 CTRP1 6.4544 7.8665 4.5778 0.9914
CL-34 CTRP1 6.7797 8.6401 4.4183 1.4889
KM12 CTRP1 6.7875 8.3372 4.5402 0.8332
MDST8 CTRP1 6.7901 8.006 4.6633 0.3389
SNU-C4 CTRP1 6.7906 7.8341 4.7235 0.1747
RCM-1 [Human ESC] CTRP1 6.8017 8.2344 4.5848 0.6219
SW948 CTRP1 6.8324 8.6632 4.4332 1.3381
NCI-H508 CTRP1 6.9189 8.4343 4.5579 0.6429
HT115 CTRP1 6.9685 8.2503 4.6435 0.3099
HCT 8 CTRP1 6.9827 8.0265 4.7255 0.1172
SNU-61 CTRP1 7.0215 8.5118 4.5702 0.5221
SNU-81 CTRP1 7.0314 8.9296 4.4171 1.1978
HT-55 CTRP1 7.0388 8.4804 4.5883 0.4475
SNU-1040 CTRP1 7.0618 8.3852 4.6306 0.304
CL-40 CTRP1 7.1431 8.2634 4.7012 0.1212
LS180 CTRP1 7.1484 8.5016 4.6217 0.2908
RKO CTRP1 7.2278 9.1617 4.4121 1.0263
SW620 CTRP1 7.2904 8.8123 4.5651 0.387
SNU-C5 CTRP1 7.2983 9.3237 4.3802 1.1111
COLO 678 CTRP1 7.5732 9.6204 4.3822 0.8664
LoVo CTRP1 7.681 9.955 4.3012 1.128
SNU-C2A CTRP1 7.7658 14.034 2.5767 12.0023
SW480 CTRP1 7.9642 9.9287 4.422 0.4859
SW403 CTRP1 7.9759 12.8425 3.2452 7.1533
⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-6 CTRP1 5.8276 9.279 3.5501 10.5685
Hep-G2 CTRP1 7.0219 8.5544 4.5548 0.5799
SNU-398 CTRP1 7.2188 10.1839 3.9938 3.5218
SNU-449 CTRP1 8.1093 9.8487 4.5018 0.2373
Cancer Drug Sensitivity Data Curated from 91 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1963 CTRP1 3.6441 6.339 3.0441 24.8329
NCI-H1755 CTRP1 5.0089 6.0746 4.5088 5.1687
NCI-H1105 CTRP1 5.3604 7.8199 3.9209 9.0518
HCC78 CTRP1 5.5292 11.0478 2.4468 19.8791
T3M-10 CTRP1 5.604 7.3083 4.3496 4.4568
NCI-H522 CTRP1 5.6386 11.3508 2.382 19.8722
NCI-H1568 CTRP1 5.7172 12.6703 1.7869 23.0255
HCC15 CTRP1 5.7738 8.0258 4.1207 5.9071
NCI-H2141 CTRP1 5.7863 7.9501 4.1653 5.489
NCI-H2029 CTRP1 5.8155 10.3222 3.0281 14.7404
NCI-H1694 CTRP1 5.9036 8.6561 3.9063 7.3352
COR-L51 CTRP1 5.9068 8.5063 3.9804 6.6985
NCI-H2126 CTRP1 5.9124 11.7192 2.4106 18.6758
NCI-H810 CTRP1 5.9629 12.1184 2.2513 19.4874
NCI-H1836 CTRP1 6.0033 7.9286 4.3138 3.6656
NCI-H1048 CTRP1 6.021 12.1875 2.2612 19.22
NCI-H727 CTRP1 6.0804 8.6611 4.0213 5.8545
COR-L279 CTRP1 6.124 13.0488 1.9131 20.883
NCI-H82 CTRP1 6.1336 11.2944 2.7851 15.3902
NCI-H2110 CTRP1 6.2065 8.7485 4.0602 5.199
BEN CTRP1 6.2176 7.6535 4.5527 1.464
NCI-H23 CTRP1 6.2255 10.7145 3.1345 12.5391
COLO 668 CTRP1 6.2476 9.9229 3.532 9.3714
NCI-H1666 CTRP1 6.2553 16.3898 0.357 27.382
NCI-H1573 CTRP1 6.3258 9.2177 3.9166 6.0461
DMS 273 CTRP1 6.3379 13.1111 2.0426 19.4244
SCLC-21H CTRP1 6.3552 8.3434 4.3296 2.7658
VMRC-LCD CTRP1 6.3687 9.1307 3.9834 5.401
NCI-H1793 CTRP1 6.3778 9.7978 3.6778 7.8238
LCLC-103H CTRP1 6.3845 8.4267 4.3092 2.8566
HCC1359 CTRP1 6.3921 7.4279 4.7184 0.3868
EPLC-272H CTRP1 6.4216 9.1295 4.0159 5.0134
LXF 289 CTRP1 6.4623 9.262 3.9798 5.1988
ChaGo-K-1 CTRP1 6.4692 12.5615 2.4081 16.7856
NCI-H1435 CTRP1 6.4739 10.2464 3.5283 8.7379
Lu-65 CTRP1 6.4938 9.5652 3.8596 6.0665
LCLC-97TM1 CTRP1 6.5066 9.4105 3.9385 5.4148
EBC-1 CTRP1 6.5836 8.4924 4.3847 1.9782
NCI-H1373 CTRP1 6.6326 13.2537 2.1874 17.6168
NCI-H841 CTRP1 6.6349 8.6063 4.3627 2.0402
NCI-H2286 CTRP1 6.6575 8.3267 4.4873 1.2484
NCI-H650 CTRP1 6.6607 11.6754 2.9716 12.3811
SHP-77 CTRP1 6.6895 9.5262 3.9932 4.57
Lu-99 CTRP1 6.6982 10.9233 3.3544 9.4487
NCI-H2073 CTRP1 6.7011 8.5974 4.3986 1.7133
Calu-3 CTRP1 6.7063 11.632 3.0231 11.8761
HARA [Human squamous cell lung carcinoma] CTRP1 6.7109 10.4888 3.5661 7.797
NCI-H2009 CTRP1 6.765 11.0296 3.3474 9.3172
Calu-6 CTRP1 6.7662 13.0522 2.3802 16.0227
NCI-H1930 CTRP1 6.7758 9.68 3.9737 4.529
NCI-H1781 CTRP1 6.7761 8.836 4.3368 1.9882
HCC2935 CTRP1 6.7765 9.0067 4.2659 2.4477
KNS-62 CTRP1 6.7873 11.7741 3.0095 11.7374
RERF-LC-KJ CTRP1 6.8324 8.8492 4.3585 1.7725
NCI-H1975 CTRP1 6.8347 13.4329 2.2436 16.6508
NCI-H2405 CTRP1 6.8354 10.7754 3.5106 7.8976
HCC33 CTRP1 6.8466 12.9425 2.4891 15.0896
DV-90 CTRP1 6.8875 8.5271 4.5101 0.8818
HCC4006 CTRP1 6.888 8.917 4.3572 1.7041
COR-L23 CTRP1 6.9265 8.518 4.5298 0.7569
NCI-H1876 CTRP1 6.9554 8.589 4.5151 0.7978
NCI-H661 CTRP1 6.9706 9.1265 4.3112 1.8657
Sq-1 CTRP1 6.9714 8.8543 4.4201 1.2477
NCI-H460 CTRP1 6.9821 7.9356 4.7555 0.0733
NCI-H1915 CTRP1 6.9998 9.8339 4.029 3.677
NCI-H1437 CTRP1 7.0031 10.6613 3.6641 6.3314
CAL-12T CTRP1 7.0245 8.725 4.4925 0.8392
NCI-H1944 CTRP1 7.053 12.2223 2.9715 11.2571
COR-L88 CTRP1 7.0821 14.54 1.8803 17.9964
NCI-H2172 CTRP1 7.0949 8.8515 4.474 0.8614
SK-LU-1 CTRP1 7.1282 8.7751 4.516 0.6565
HCC827 CTRP1 7.1522 8.8099 4.5128 0.6521
NCI-H1299 CTRP1 7.1862 10.0407 4.0378 3.2812
NCI-H2030 CTRP1 7.196 8.8904 4.5006 0.6685
NCI-H441 CTRP1 7.2 9.0939 4.4262 0.986
NCI-H596 CTRP1 7.2196 8.6318 4.6023 0.3129
COLO 699 CTRP1 7.2275 8.9678 4.4846 0.7094
NCI-H2081 CTRP1 7.2864 9.3658 4.359 1.2263
HCC44 CTRP1 7.3282 9.3239 4.3927 1.0246
HCC1195 CTRP1 7.3355 8.7861 4.5908 0.2952
LC-1/sq-SF CTRP1 7.3458 13.9116 2.3627 14.4392
HCC2108 CTRP1 7.3841 8.9843 4.5393 0.4187
NCI-H3255 CTRP1 7.4233 9.0234 4.5401 0.397
NCI-H2122 CTRP1 7.4264 8.8993 4.5845 0.2762
NCI-H358 CTRP1 7.4776 15.6331 1.6265 18.2079
NCI-H2023 CTRP1 7.5354 9.31 4.4805 0.5252
NCI-H1355 CTRP1 7.6273 13.2653 2.8474 10.6032
A-549 CTRP1 7.6371 11.7245 3.5503 5.7774
HCC1833 CTRP1 7.8621 9.9553 4.3738 0.6989
NCI-H2342 CTRP1 7.8727 9.6446 4.4877 0.3464
NCI-H1792 CTRP1 8.3486 16.2326 1.9179 14.4055
⏷ Show the Full List of 91 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-410 CTRP1 6.7571 10.0317 3.8047 5.8481
KYSE-450 CTRP1 6.86 10.7793 3.524 7.7327
KYSE-140 CTRP1 6.8795 10.4564 3.6841 6.4731
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COV434 CTRP1 5.2559 8.8042 3.3478 14.3604
OVKATE CTRP1 6.1436 10.5055 3.1781 12.4756
OAW42 CTRP1 6.4003 7.6352 4.6441 0.706
OVK18 CTRP1 6.53 12.2135 2.6211 15.2083
JHOC-5 CTRP1 6.5556 8.7199 4.2739 2.7819
Caov-3 CTRP1 6.6697 8.3215 4.4949 1.1915
JHOM-1 CTRP1 6.7449 8.7085 4.3741 1.8013
OV7 CTRP1 6.7942 8.6917 4.4042 1.5517
JHOS-4 CTRP1 6.8206 14.0011 1.9573 18.3588
OVMANA CTRP1 6.8382 8.1049 4.6463 0.3677
COV362 CTRP1 6.8818 9.057 4.2971 2.08
HEY A8 CTRP1 6.9282 10.0647 3.8887 4.8325
SK-OV-3 CTRP1 6.9977 9.763 4.0584 3.4754
OVCAR-4 CTRP1 7.092 11.1467 3.4961 7.3671
EFO-27 CTRP1 7.1982 9.2217 4.3765 1.2291
COV644 CTRP1 7.253 8.982 4.4896 0.6711
OV-90 CTRP1 7.3121 8.9022 4.5414 0.4495
OVCAR-8 CTRP1 7.3618 9.0699 4.5002 0.5597
TYK-nu CTRP1 7.4123 9.054 4.5251 0.448
RMG-I CTRP1 7.4277 10.2191 4.0835 2.6031
IGROV-1 CTRP1 7.472 9.4901 4.3897 0.915
SNU-840 CTRP1 7.5568 12.6313 3.0964 9.0972
A2780 CTRP1 7.8997 9.8236 4.4351 0.4782
RMUG-S CTRP1 8.2468 15.7501 2.079 13.7666
COV318 CTRP1 8.36 13.7469 3.0597 7.5782
EFO-21 CTRP1 9.7096 18.7559 1.5884 13.0966
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuP-T4 CTRP1 6.1565 9.8243 3.5173 9.7691
QGP-1 CTRP1 6.5194 9.1586 4.0603 4.4396
HPAC CTRP1 6.5254 9.4831 3.9166 5.5403
PaTu 8902 CTRP1 6.5538 9.9382 3.724 6.9805
Panc 10.05 CTRP1 6.7837 8.9715 4.2843 2.3146
SUIT-2 CTRP1 6.7883 9.1805 4.1984 2.8852
KP-3 CTRP1 7.0874 10.1158 3.9538 4.0398
Capan-2 CTRP1 7.1308 11.4001 3.4034 7.9527
CFPAC-1 CTRP1 7.4481 9.1297 4.5117 0.4714
Panc 03.27 CTRP1 7.4543 12.9797 2.8723 10.873
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H CTRP1 6.6432 10.8059 3.3742 9.4527
NCI-H28 CTRP1 6.7428 9.5536 4.0112 4.3201
NCI-H2052 CTRP1 7.1895 9.5612 4.2382 2.0023
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PaCa-3 CTRP1 9.2119 16.8289 2.1688 11.1156
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Hs 852.T CTRP1 5.9942 10.9977 2.8283 15.5662
COLO 741 CTRP1 6.0842 11.3922 2.7008 16.1447
SK-MEL-28 CTRP1 6.3526 7.1508 4.802 0.1453
SK-MEL-1 CTRP1 6.8028 7.9621 4.6836 0.2715
G-361 CTRP1 6.8906 11.294 3.3036 9.3046
SK-MEL-5 CTRP1 6.9751 8.3067 4.6261 0.3591
Hs 944.T CTRP1 7.289 12.0955 3.1798 9.1705
Hs 936.T CTRP1 7.5099 15.7758 1.58 18.3559
A-375 CTRP1 7.6887 9.3191 4.5339 0.3019
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HT-1080 CTRP1 6.2618 7.872 4.4832 1.8535
RKN CTRP1 7.0699 8.4493 4.6111 0.3572
G-401 CTRP1 7.6341 14.339 2.3494 13.7416
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NUGC-4 CTRP1 5.0473 14.1361 0.5106 31.0303
MKN7 CTRP1 6.5599 8.921 4.1887 3.3878
Fu97 CTRP1 6.5927 9.184 4.0909 4.0458
MKN74 CTRP1 7.1007 10.7266 3.6914 5.9078
AGS CTRP1 7.3339 8.7895 4.5891 0.3004
SH-10-TC CTRP1 7.6704 12.9007 3.0415 9.2005
SNG-M CTRP1 6.8705 8.5202 4.5056 0.9199
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-2 CTRP1 6.5326 10.9066 3.2533 10.6896
SCC-9 CTRP1 7.6172 9.269 4.5254 0.3515
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
5637 CTRP1 6.4121 10.5897 3.3237 10.5117
HT-1376 CTRP1 6.6279 9.543 3.9501 5.0371
UM-UC-3 CTRP1 6.8568 9.6111 4.0489 3.8113
RT-4 CTRP1 6.9195 10.5329 3.673 6.4611
KMBC-2 CTRP1 8.7921 17.4304 1.6385 14.8208

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Maraviroc
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Cobicistat DM6L4H2 Moderate Decreased metabolism of Maraviroc caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [8]
Etravirine DMGV8QU Moderate Increased metabolism of Maraviroc caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [8]
Coadministration of a Drug Treating the Disease Different from Maraviroc (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sarecycline DMLZNIQ Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [9]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Maraviroc caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [8]
Midostaurin DMI6E0R Moderate Decreased metabolism of Maraviroc caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [9]
Arn-509 DMT81LZ Major Increased metabolism of Maraviroc caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [9]
Gilteritinib DMTI0ZO Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [9]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Maraviroc caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [9]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Maraviroc and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [10]
Troleandomycin DMUZNIG Major Decreased metabolism of Maraviroc caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [9]
Erdafitinib DMI782S Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [11]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Maraviroc and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [12]
HKI-272 DM6QOVN Moderate Decreased clearance of Maraviroc due to the transporter inhibition by HKI-272. Breast cancer [2C60-2C6Y] [9]
Tucatinib DMBESUA Major Decreased metabolism of Maraviroc caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [9]
Palbociclib DMD7L94 Moderate Decreased metabolism of Maraviroc caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [9]
Alpelisib DMEXMYK Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Alpelisib. Breast cancer [2C60-2C6Y] [9]
PF-04449913 DMSB068 Moderate Decreased clearance of Maraviroc due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [9]
Ulipristal DMBNI20 Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Ulipristal. Contraceptive management [QA21] [9]
Lumacaftor DMCLWDJ Major Increased metabolism of Maraviroc caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [9]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Maraviroc caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [9]
MK-8228 DMOB58Q Moderate Decreased clearance of Maraviroc due to the transporter inhibition by MK-8228. Cytomegaloviral disease [1D82] [9]
Cenobamate DM8KLU9 Moderate Increased metabolism of Maraviroc caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [8]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Maraviroc caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [8]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Maraviroc and Cannabidiol. Epileptic encephalopathy [8A62] [13]
Tazemetostat DMWP1BH Moderate Increased metabolism of Maraviroc caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [8]
Boceprevir DMBSHMF Major Decreased metabolism of Maraviroc caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [9]
Telaprevir DMMRV29 Major Decreased metabolism of Maraviroc caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [9]
Daclatasvir DMSFK9V Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Daclatasvir. Hepatitis virus infection [1E50-1E51] [9]
GS-5885 DMSL3DX Moderate Decreased clearance of Maraviroc due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [9]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Maraviroc and Brentuximab vedotin. Hodgkin lymphoma [2B30] [14]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Maraviroc and Mipomersen. Hyper-lipoproteinaemia [5C80] [15]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Maraviroc and Teriflunomide. Hyper-lipoproteinaemia [5C80] [16]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Maraviroc and BMS-201038. Hyper-lipoproteinaemia [5C80] [17]
Tolvaptan DMIWFRL Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [9]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Maraviroc caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [9]
Suvorexant DM0E6S3 Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Suvorexant. Insomnia [7A00-7A0Z] [9]
Crizotinib DM4F29C Moderate Decreased metabolism of Maraviroc caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [9]
Brigatinib DM7W94S Moderate Increased metabolism of Maraviroc caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [18]
Ceritinib DMB920Z Major Decreased metabolism of Maraviroc caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [9]
PF-06463922 DMKM7EW Moderate Accelerated clearance of Maraviroc due to the transporter induction by PF-06463922. Lung cancer [2C25] [8]
Capmatinib DMYCXKL Moderate Decreased metabolism of Maraviroc caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [9]
Selpercatinib DMZR15V Moderate Decreased metabolism of Maraviroc caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [9]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Maraviroc and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [19]
Idelalisib DM602WT Major Decreased metabolism of Maraviroc caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [9]
Ibrutinib DMHZCPO Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Ibrutinib. Mature B-cell lymphoma [2A85] [13]
Ponatinib DMYGJQO Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Ponatinib. Mature B-cell lymphoma [2A85] [9]
Vemurafenib DM62UG5 Moderate Increased metabolism of Maraviroc caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [8]
Lasmiditan DMXLVDT Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Lasmiditan. Migraine [8A80] [20]
Flibanserin DM70DTN Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Flibanserin. Mood disorder [6A60-6E23] [9]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Maraviroc and Ozanimod. Multiple sclerosis [8A40] [21]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Maraviroc caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [9]
Nilotinib DM7HXWT Moderate Decreased metabolism of Maraviroc caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [9]
Rolapitant DM8XP26 Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [22]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Maraviroc caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [9]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Maraviroc and Safinamide. Parkinsonism [8A00] [21]
Istradefylline DM20VSK Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Istradefylline. Parkinsonism [8A00] [9]
Abametapir DM2RX0I Moderate Decreased metabolism of Maraviroc caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [23]
Lefamulin DME6G97 Moderate Decreased metabolism of Maraviroc caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [24]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Maraviroc caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [9]
Enzalutamide DMGL19D Major Increased metabolism of Maraviroc caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [9]
Voxelotor DMCS6M5 Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Voxelotor. Sickle-cell disorder [3A51] [9]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Maraviroc caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [13]
Larotrectinib DM26CQR Moderate Decreased metabolism of Maraviroc caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [9]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Maraviroc and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [13]
Armodafinil DMGB035 Moderate Increased metabolism of Maraviroc caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
LEE011 DMMX75K Moderate Decreased metabolism of Maraviroc caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [9]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Maraviroc caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [25]
Brilinta DMBR01X Moderate Decreased metabolism of Maraviroc caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [9]
Cabozantinib DMIYDT4 Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Cabozantinib. Thyroid cancer [2D10] [9]
Elagolix DMB2C0E Moderate Increased metabolism of Maraviroc caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [8]
⏷ Show the Full List of 68 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Calcium hydrogenphosphate E00294 24441 Diluent
Magnesium stearate E00208 11177 lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Maraviroc 150 mg tablet 150 mg Oral Tablet Oral
Maraviroc 25 mg tablet 25 mg Oral Tablet Oral
Maraviroc 300 mg tablet 300 mg Oral Tablet Oral
Maraviroc 75 mg tablet 75 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 806).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9.
6 Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005 Dec 19;71(1-2):163-72.
7 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
8 Cerner Multum, Inc. "Australian Product Information.".
9 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
10 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
11 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
12 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
13 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
14 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
15 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
16 Canadian Pharmacists Association.
17 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
18 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
19 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
20 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
21 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
22 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
23 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
24 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
25 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.